Cimduo FDA Approval History
FDA Approved: Yes (First approved February 28, 2018)
Brand name: Cimduo
Generic name: lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Mylan Pharmaceuticals Inc.
Treatment for: HIV Infection
Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Development Timeline for Cimduo
|Mar 2, 2018||Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.|